A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Clinical trial NCT06629779 · RECRUITING

Trial details

NCT number: NCT06629779
Sponsor: Pfizer
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Metastatic Castration-Resistant Prostate Cancer

Start date: 2024-10-22
Primary completion: 2026-12-02
Enrollment: 900

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.